Tuesday, 23 Apr 2019

You are here

Pilot Data on Rituximab in Henoch-Schonlein Purpura

Management of Henoch-Schonlein purpura (HSP) can be challenging as supportive care and avoidance of corticosteroids (CS) are often insufficient options. A new series of case reports and literature review of steroid refractory HSP suggests that rituximab (RTX) may be effective in reducing hospital admissions, overall steroid use, and is capable of inducing remission.

A minority of HSP cases are so severe with either persistent rash, arthritis, abdominal involvement, or renal disease, that CS are needed. Other alternatives for steroid sparing are few.

Crayne et al describes 8 children treated with RTX for chronic refractory HSP.  Patients were identified by retrospective review of data between 2006–2014 at a single institution.

Prior to RTX, 7/8 had at least one hospitalization for HSP (median 1.5, range 0–3).

Following RTX, only 2/8 were hospitalized.  With RTX use, oral CS use fell significantly from 0.345 mg/kg/day before RTX to 0 mg/kg/day at 6 months (p = 0.078), 1 year (p = 0.0625), and 2 years (p = 0.03) following RTX infusion.

Ultimately 7/8 remission criteria (no active rash, arthritis, nephritis (hematuria or proteinuria), or gastrointestinal involvement). 

The authors also describe another eight, mostly single case, reports of RTX use in adults and children with HSP - all with beneficial outcomes. 

The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

EULAR 2019 Update to Lupus Management

The goal of SLE treatment is remission or low disease activity and flare prevention. Hydroxychloroquine is recommended in all patients with lupus, at a dose not exceeding 5 mg/kg real body weight. Glucocorticoids (GC) should be minimised to less than 7.5 mg/day (prednisone equivalent). Appropriate initiation of immunomodulatory agents (methotrexate, azathioprine, mycophenolate) can be tailored to the clinical scenarios and may allow for tapering or discontinuation of GC.

Mortality Risk Factors in Systemic Sclerosis

A French cohort study of 625 systemic sclerosis (SStc) patients has found a significantly increased mortality risk that can be predicted by common clinical variables.

In addition to a multicenter prospective study, investigators performed a metanalysis on SSc standarized mortality ratios (SMR) and hazard ratios of prognosis factors.

Better Tests Ahead in Lupus

The advent of "big data" and "-omics" technologies offers hope that clinicians will soon have better diagnostics for systemic lupus erythematosus, rheumatologists here were told.

GCA Relapse Risk High with Steroids

Prior to the introduction of tocilizumab to manage giant cell arteritis (GCA), glucocorticoids (GC) have been the mainstay of therapy, but has been limited by relapses in disease. A recent metanalysis shows that relapses occur in nearly half of patients and are related to the duration of therapy rather than the initial dose of GC.

A literature review found 34 studies (2,505 patients) from 8 RCTs of GCA patients only treated with GC.

Presenting Features of Early SLE

What clinical features best identify early systemic lupus erythematosus (SLE) patients from mimics?  A multicenter, multinational study aimed to evaluate manifestations at disease onset and to compare early SLE manifestations to those of diseases mimicking SLE.